 |
市场调查报告书
商品编码
2003653
普崙司特市场规模、份额和成长分析：按剂量效力、剂型、患者群体、治疗应用、分销管道和地区划分 - 行业预测，2026-2033 年Pranlukast Market Size, Share, and Growth Analysis, By Dosage Strength (75 MG, 150 MG), By Formulation (Tablets, Inhalers), By Patient Demographics, By Therapeutic Use, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
2024 年全球普崙司特市场价值为 17 亿美元，预计到 2033 年将从 2025 年的 17.7 亿美元增长至 24.6 亿美元，预测期（2026-2033 年）的复合年增长率为 4.2%。
全球普崙司特市场主要受慢性呼吸系统疾病和过敏性疾病日益普遍的推动，促使口服白三烯受体拮抗剂在门诊治疗中得到应用。该市场涵盖品牌药和非专利普崙司特产品，并受益于口服治疗，从而提高了患者的依从性，尤其是在吸入器使用困难的情况下。由于价格更低、医保覆盖范围更广以及医疗服务提供者接受度更高，非专利药的普及扩大了药物的可及性，尤其是在门诊治疗中，儿童和老年人等患者群体受益匪浅。此外，人工智慧正在革新研发和商业化流程，透过简化化合物选择、降低风险、透过新的给药方法提高患者依从性、优化市场细分以及在日益激烈的非专利竞争中优化产品部署，从而推动市场成长。
全球普崙司特市场的成长要素
气喘及相关过敏性呼吸系统疾病的日益普遍，使得更多患者能够从普崙司特等靶向白三烯受体拮抗剂中获益，从而促使人们对该治疗领域投入更多资金和关注。当传统治疗方法无法有效控制病情时，医疗专业人员会积极寻求替代疗法，这使得人们对作用机制多样的药物产生了浓厚的兴趣。这种不断增长的临床需求推动了研究活动，促进了市场准入，并提高了医疗专业人员的认知度，所有这些因素共同促成了全球市场对普崙司特相关产品需求的显着增长和持续攀升。
全球普崙司特市场的限制因素
由于副作用报告和对其长期安全性的担忧，全球普崙司特市场面临挑战。这些问题导致处方医生持谨慎态度，他们往往更倾向于选择广为人知、广为接受且成熟的治疗方法。安全性考量在临床决策中起着至关重要的作用，通常需要加强监测和风险管理策略，这可能会限制某些病患小组群体对该药物的使用。医护人员和患者的这种谨慎态度正在减缓处方趋势和市场渗透率。此外，这也促使生产商加强对安全性研究和教育计画的投入，以促进普崙司特的更广泛应用。
全球普崙司特市场趋势
全球普崙司特市场正经历着向精准医疗的显着转变，这主要得益于药物基因体学和生物标记相关策略的推动，这些策略能够根据个别患者的特征优化治疗方法。诊断工具和数位化用药依从性项目的整合，使医疗专业人员能够识别出最能从白三烯受体拮抗剂中获益的患者，从而优化剂量并监测疗效。製药公司与诊断设备製造商之间的合作正在推动产品标籤的完善，并支持精准行销。这种个人化方法不仅增强了人们对临床结果和医生处方的信心，还创造了独特的价值提案，有助于在特定细分市场进行策略性定价和合约执行。
目录
介绍
- 调查目的
- 市场定义和范围
调查方法
- 研究过程
- 二级资料和一级资料的方法
- 市场规模估算方法
执行摘要
- 全球市场展望
- 市场主要亮点
- 细分市场概览
- 竞争环境概述
市场动态及展望
- 总体经济指标
- 促进者和机会
- 抑制因素和挑战
- 供给面趋势
- 需求面趋势
- 波特的分析和影响
关键市场分析
- 关键成功因素
- 影响市场的因素
- 主要投资机会
- 生态系测绘
- 2025年市场魅力指数
- PESTLE分析
- 监理情势
- 价格分析
- 专利分析
全球普崙司特市场规模：依效力划分
- 75 mg
- 150 mg
- 300 mg
全球普崙司特市场规模：以剂型划分
- 药片
- 吸入器
- 其他的
全球普崙司特市场规模：依患者群体划分
- 儿童
- 成人
- 老年人
全球普崙司特市场规模：依治疗应用划分
- 气喘
- 慢性阻塞性肺病（COPD）
全球普崙司特市场规模：依分销管道划分
- 医院药房
- 零售药房
- 网路药房
全球普崙司特市场规模：依地区划分
- 北美洲
- 我们
- 加拿大
- 欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太国家
- 拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲国家
- 中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲国家
竞争资讯
- 前五大公司对比
- 主要企业2025年的市场定位
- 主要市场公司采取的策略
- 近期市场趋势
- 企业市场占有率分析，2025 年
- 主要企业公司简介
- 公司详情
- 产品系列分析
- 按细分市场进行企业市占率分析
- 销售收入年比比较（2023-2025 年）
主要企业简介
- Mylan
- Teva Pharmaceuticals
- Cipla
- Sun Pharmaceutical Industries
- Aurobindo Pharma
- Hikma Pharmaceuticals
- Sandoz
- Zydus Cadila
- Amgen
- GSK
- Roche
- AbbVie
- Pfizer
- Merck & Co.
- Johnson & Johnson
- Novartis
- Sanofi
- Bayer
- Eli Lilly
- Boehringer Ingelheim
结论与建议
Global Pranlukast Market size was valued at USD 1.7 Billion in 2024 and is poised to grow from USD 1.77 Billion in 2025 to USD 2.46 Billion by 2033, growing at a CAGR of 4.2% during the forecast period (2026-2033).
The global pranlukast market is significantly driven by the increasing prevalence of chronic respiratory and allergic conditions, which promote the use of oral leukotriene receptor antagonists for outpatient care. This market encompasses both branded and generic forms of pranlukast, particularly benefitting from oral therapies that enhance patient adherence, especially when inhalers are challenging to use. The shift toward generic offerings is expanding access as lower prices increase payer coverage and provider acceptance, especially in outpatient settings catering to populations such as children and the elderly. Furthermore, AI is revolutionizing R&D and commercialization by streamlining compound selection, reducing risks, enhancing patient adherence through novel delivery methods, refining market segmentation, and optimizing rollouts amidst rising generic competition, thereby propelling market growth.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pranlukast market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Pranlukast Market Segments Analysis
Global pranlukast market is segmented by dosage strength, formulation, patient demographics, therapeutic use, distribution channel and region. Based on dosage strength, the market is segmented into 75 MG, 150 MG and 300 MG. Based on formulation, the market is segmented into Tablets, Inhalers and Others. Based on patient demographics, the market is segmented into Pediatric, Adult and Geriatric. Based on therapeutic use, the market is segmented into Asthma and Chronic Obstructive Pulmonary Disease (COPD). Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Pranlukast Market
The increasing prevalence of asthma and associated allergic respiratory conditions has broadened the patient base that stands to gain from targeted leukotriene receptor antagonists like pranlukast, driving investment and attention in this therapeutic area. Medical professionals are actively seeking alternatives when traditional treatments do not achieve adequate control, leading to a heightened interest in medications with varied mechanisms of action. This escalating clinical requirement fuels research initiatives, aids in market entry efforts, and enhances awareness among healthcare providers, all of which contribute to a significant surge in demand and ongoing growth for pranlukast-related products within the global market.
Restraints in the Global Pranlukast Market
The global pranlukast market faces challenges due to reports of adverse reactions and concerns regarding long-term safety profiles. These issues lead to a degree of caution among prescribers who may prefer established therapies that are well-known and widely accepted. Safety considerations play a significant role in clinical decision-making, often requiring enhanced monitoring or risk management strategies that can limit the drug's adoption within specific patient groups. This cautious approach from both healthcare providers and patients consequently slows down the prescribing momentum and market penetration. Additionally, it drives manufacturers to invest in further safety studies and educational programs to foster broader acceptance of pranlukast.
Market Trends of the Global Pranlukast Market
The global Pranlukast market is witnessing a significant trend towards precision medicine, driven by pharmacogenomic and biomarker-related strategies that tailor therapies to individual patient profiles. The integration of diagnostic tools and digital adherence programs empowers healthcare providers to pinpoint patients who will most benefit from leukotriene receptor antagonism, facilitating optimized dosing and response monitoring. Collaborations between pharmaceutical companies and diagnostics firms enhance the refining of product labels and support targeted marketing efforts. This personalized approach not only boosts clinical outcomes and prescribing confidence among physicians but also creates unique value propositions that contribute to strategic pricing and contracting in specialized market segments.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
- Pricing Analysis
- Patent Analysis
Global Pranlukast Market Size by Dosage Strength & CAGR (2026-2033)
- Market Overview
- 75 MG
- 150 MG
- 300 MG
Global Pranlukast Market Size by Formulation & CAGR (2026-2033)
- Market Overview
- Tablets
- Inhalers
- Others
Global Pranlukast Market Size by Patient Demographics & CAGR (2026-2033)
- Market Overview
- Pediatric
- Adult
- Geriatric
Global Pranlukast Market Size by Therapeutic Use & CAGR (2026-2033)
- Market Overview
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
Global Pranlukast Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Pranlukast Market Size & CAGR (2026-2033)
- North America (Dosage Strength, Formulation, Patient Demographics, Therapeutic Use, Distribution Channel)
- US
- Canada
- Europe (Dosage Strength, Formulation, Patient Demographics, Therapeutic Use, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Dosage Strength, Formulation, Patient Demographics, Therapeutic Use, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Dosage Strength, Formulation, Patient Demographics, Therapeutic Use, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Dosage Strength, Formulation, Patient Demographics, Therapeutic Use, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Mylan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurobindo Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hikma Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Cadila
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GSK
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
